Press Releases

For press releases issued prior to June 2, 2014, the date of the spin-off of Theravance Biopharma, Inc. from Theravance, Inc., please visit Innoviva, Inc.

Date Title  
08/01/18
TD-1473 Advancing into Phase 2b/3 Study in Ulcerative Colitis in Fourth Quarter Following Completion of Phase 1b Study and Successful Dialogues with FDA and EMA TD-1473 Advancing into Phase 2 Study in Crohn's Disease in Third Quarter TD-9855 Advancing into Phase 3 Program in nOH in Late 2018 or
08/01/18

Durable Improvements in nOH Symptom Severity Observed as Measured by OHSA Question #1 Findings Demonstrate Consistent Increases in Systolic Blood Pressure (SBP), Including Clinically Meaningful Improvements in Standing SBP at All Time Points Company Plans to Progress TD-9855 into Registrational

07/25/18

DUBLIN , July 25, 2018 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) (" Theravance Biopharma " or the "Company") today announced that it will release financial results for the period ended June 30, 2018 and provide a business update before market open on Wednesday, August 1, 2018 .

05/29/18

DUBLIN , May 29, 2018 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) (" Theravance Biopharma ") today highlighted that a regulatory application for once-daily fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI 100/62.5/25 mcg) under the proposed brand name Trelegy Ellipta has been

05/17/18

Live Event and Webcast from 12:00 - 1.30 p.m. ET on Thursday, May 24th DUBLIN , May 17, 2018 /PRNewswire/ --   Theravance Biopharma, Inc. (NASDAQ: TBPH) today announced that it will host a key opinion leader event focusing on neurogenic orthostatic hypotension (nOH) beginning at 12:00 p.m.

05/10/18

DUBLIN , May 10, 2018 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) announced today that Rick E Winningham, Chairman and Chief Executive Officer will participate in a fireside chat at the Bank of America Merrill Lynch 2018 Healthcare Conference on Thursday, May 17, 2018 , at 10:40 a.m.

05/08/18
Focusing on Advancement of Highest Priority Programs DUBLIN , May 8, 2018 /PRNewswire/ -- Theravance Biopharma, Inc. (" Theravance Biopharma " or the "Company") (NASDAQ: TBPH) today reported financial results for the first quarter ended March 31, 2018 .
05/01/18

DUBLIN , May 1, 2018 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) (" Theravance Biopharma " or the "Company") today announced that it will release financial results for the period ended March 31, 2018 and provide a business update after market close on Tuesday, May 8, 2018 .

04/25/18

DUBLIN , April 25, 2018 /PRNewswire/ --  Theravance Biopharma, Inc. (NASDAQ: TBPH) (" Theravance Biopharma ") today highlighted that the US Food and Drug Administration ( FDA ) has approved an expanded indication for Trelegy Ellipta. This expanded approval in the US allows Trelegy Ellipta to be

04/23/18

Data from TOUR™ Observational Patient Registry Demonstrate Clinical Response Rates with VIBATIV® (telavancin) Treatment Range from 76.5 - 78.8% for Obese and Elderly Patient Subgroups Additional Study Results Demonstrate VIBATIV to Have 8- to 32-Fold Greater in vitro Potency than Competitor